Tag Archives: Sanofi’s Wayrilz Receives Japan Approval for Persistent and Chronic Immune Thrombocytopenia

Japan Authorises Sanofi’s Wayrilz for Patients With Difficult-to-Treat Immune Thrombocytopenia

Posted on 24, June 2026 by EuropaWire PR Editor

(IN BRIEF) Sanofi’s Wayrilz® (rilzabrutinib) has received approval in Japan for the treatment of persistent or chronic immune thrombocytopenia in patients who have not responded sufficiently to other therapies or have tolerability concerns with existing options. The authorization is based … Read the full press release →

Posted in France, Healthcare, Pharma & Biotech, Science, Security & Safety, Technology

Tagged abdominal pain, bleeding risk, Bruton’s tyrosine kinase inhibitor, BTKi, chronic ITP, clinical research, diarrhoea, durable platelet response, headache, Hisashi Kato, IgG4-related disease, immune thrombocytopenia, ITP, Japan, Japan Approval Adds Wayrilz to Treatment Options for Persistent or Chronic ITP, LUNA 3, Manuela Buxo, Ministry of Health Labour and Welfare, multi-immune modulation, nausea, orphan drug designation, persistent ITP, Phase 3 clinical trial, platelet counts, platelet response, quality of life, rare disease, rilzabrutinib, Sanofi, Sanofi Expands ITP Treatment Portfolio With Wayrilz Approval in Japan, Sanofi’s Wayrilz Receives Japan Approval for Persistent and Chronic Immune Thrombocytopenia, sickle cell disease, specialty care, warm autoimmune haemolytic anaemia, Wayrilz, Wayrilz Approved in Japan Following Positive Phase 3 LUNA 3 Results in Immune Thrombocytopenia